Project Grant RF1NS128607
Award Date
8/17/22
Completion Date
7/31/25
Dollars Obligated
$3.5M
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Piscataway, NJ 08854, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $655,638 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Denver. The grant, which runs from September 2024 to February 2027, will support research to develop synthetic protein mimetics as potential therapeutics for Lewy Body Dementia (LBD). The project aims to optimize the pharmaceutical properties and efficacy of these synthetic protein mimetics in inhibiting alpha-synuclein aggregation and...
This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $795,436 to Rutgers, The State University of New Jersey to conduct a postmortem study examining the role of the brain glycoproteome in Alzheimer's disease and related dementias (AD/ADRD). The study aims to: Identify glycopeptiforms (glycosylated proteins) related to AD/ADRD pathologies and clinical traits like cognitive decline. Test if glycopeptiforms linked to an active lifestyle mediate the...
The National Institute on Aging (NIA) awarded a $2,069,215 Project Grant (CFDA 93.866) to Case Western Reserve University (CWRU) to investigate the role of the beta-arrestin2-LMBRD2 cascade in the pathogenesis of alpha-synuclein, a key protein involved in Lewy body diseases like Parkinson's disease and dementia with Lewy bodies. The research aims to elucidate the mechanisms governing the internalization and transmission of pathological alpha-synuclein, which is critical for understanding disease...
The National Institute on Aging (NIA) awarded a $791,086 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to the Northern California Institute for Research and Education, Inc. (NCIRE) to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes (non-ADNC), such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The project...
This federal Project Grant award, valued at $1,671,360.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The purpose of the award is to support research investigating the role of polarity dysregulation in Alzheimer's disease (AD) progression. Specifically, the research aims to test the hypothesis that loss of the polarity protein PAR3 disrupts...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of synaptic autophagy in Alzheimer's disease (AD) pathogenesis and evaluate if optimizing synaptic autophagy can provide neuroprotection in an AD mouse model. The $628,000 award to Rutgers, The State University of New Jersey, runs from January 1, 2025 to December 31, 2026. The project will utilize primary hippocampal cell cultures and AD mouse models to determine...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $1,641,495 will fund research at the University of Florida to investigate the molecular mechanisms by which mutations in the GBA1 gene influence the development of Lewy Body Dementia (LBD). The project will use induced pluripotent stem cell-derived neurons, both wildtype and with pathogenic GBA1 mutations, to examine how GBA1 impacts the regulation, trafficking, and maturation of key lysosomal...
This $2,253,665 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the pathomechanisms of apolipoprotein E4 (APOE4), a major genetic risk factor for Lewy body dementia (LBD), and its influence on alpha-synuclein pathology. The primary research objectives are to: 1) conduct multi-omics profiling of human LBD brains to uncover lipid and endosomal-lysosomal dysfunction associated with APOE4, 2) use astrocyte-specific APOE3 or APOE4...
This Project Grant award of $752,589 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the relationship between protein aggregates in peripheral nerves and pathology in the brains of individuals with Alzheimer's disease and related dementias. The central hypothesis is that non-dominant protein aggregates can impact the progression and symptoms of dementia. Specifically, the research aims to: Determine the relationship between pathology in...